Daewoong Nabota, Patent for Migraine Treatment in the US... "Accelerating Entry into the Treatment Market"

Exclusive Patent Rights for Migraine Treatment Until 2041

Daewoong Pharmaceutical announced on the 7th that it has obtained a patent in the United States for the use of its botulinum toxin (BTX) product 'Nabota' in the treatment of migraines.

Daewoong Pharmaceutical's botulinum toxin product 'Nabota'.
[Photo by Daewoong Pharmaceutical]

This patent acquisition was achieved through Daewoong Pharmaceutical's U.S. partner, Ion Biopharma. Ion Biopharma received a patent from the United States Patent and Trademark Office (USPTO) for BTX 'ABP-450' (the Korean product name Nabota) as a 'Neurotoxin Composition for Use in Treating Headache.'

Ion Biopharma was granted the patent in recognition of improvements over existing BTX formulations by reducing the number of administrations while changing the injection sites to enhance ease of use and reduce side effects. This patent grants exclusive rights in the U.S. until 2041.

A Daewoong Pharmaceutical official explained, "With this migraine patent for Nabota, we expect Ion Biopharma’s ongoing Phase 2 clinical trials in the U.S. for episodic (intermittent) migraine and chronic migraine treatments to proceed smoothly."

Daewoong Pharmaceutical is targeting the global market focusing on treatment indications with high market potential. According to market research firm Fortune Business Insights, the global BTX market was valued at $6.5 billion (approximately 8.3 trillion KRW) last year, with 53% of that accounted for by the therapeutic market.

Daewoong Pharmaceutical plans to expand the range of treatment indications to include ▲ episodic and chronic migraine ▲ cervical dystonia ▲ gastroparesis ▲ post-traumatic stress disorder (PTSD), among others. The company views this patent, which protects the exclusive method of use related to Nabota’s therapeutic indications, as a stepping stone to accelerate entry into the BTX treatment market.

Park Sung-soo, Vice President of Daewoong Pharmaceutical, said, "With this migraine patent for Nabota, we expect to become the second in the world to receive approval for migraine treatment indications. Through close cooperation with Ion Biopharma, we will achieve rapid market entry for Nabota’s therapeutic indications."

Meanwhile, Ion Biopharma is a U.S.-based company specializing in the research and development of BTX biopharmaceuticals. Daewoong Pharmaceutical signed a partnership agreement with Ion Biopharma in 2019 for Nabota’s global therapeutic business. Recently, Ion Biopharma was listed on the U.S. stock market, securing $125 million (approximately 167 billion KRW) in investment funds, and is accelerating clinical trials to expand Nabota’s therapeutic indications.

Ion Biopharma is preparing to announce the topline results of the Phase 2 clinical trial for episodic migraine indications in the second half of this year, and plans to announce topline results for chronic migraine indications in Phase 2 next year. The cervical dystonia indication is expected to complete Phase 2 this year and enter Phase 3 next year. The gastroparesis indication has submitted a Phase 2 clinical trial application plan, and the post-traumatic stress disorder (PTSD) indication is currently in the preclinical stage.

This content was produced with the assistance of AI translation services.